Lotus Pharmaceutical Co., Ltd. Stocks

NT$ 283.5Last Updated 07.11.2025

Issuer Rating

5/7

Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

NT$ 2.37B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 283.5
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it...

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 1795.TW is 363 and suggests 30% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks